Safety and immunogenicity of different formulations of norovirus vaccine candidate in healthy adults: a randomized, controlled, double-blind clinical trial

G Leroux-Roels, JP Cramer… - The Journal of …, 2018 - academic.oup.com
Background We investigated safety and immunogenicity of 1–2 doses of different bivalent
virus-like particle (VLP) norovirus vaccine candidate (NoV) formulations in healthy 18-to 64 …
被引用次数：77 相关文章
[PDF] oup.com

[PDF][PDF] Safety and Immunogenicity of Different Formulations of Norovirus Vaccine Candidate in Healthy Adults: A Randomized, Controlled, Double-Blind Clinical Trial

G Leroux-Roels, JP Cramer… - The Journal of …, 2018 - academic.oup.com
Background We investigated safety and immunogenicity of 1–2 doses of different bivalent
virus-like particle (VLP) norovirus vaccine candidate (NoV) formulations in healthy 18-to 64 …

Safety and Immunogenicity of Different Formulations of Norovirus Vaccine Candidate in Healthy Adults: A Randomized, Controlled, Double-Blind Clinical Trial

G Leroux-Roels, JP Cramer, PM Mendelman… - The Journal of Infectious …, 2018 - JSTOR
Background. We investigated safety and immunogenicity of 1–2 doses of different bivalent
virus-like particle (VLP) norovirus vaccine candidate (NoV) formulations in healthy 18-to 64 …
[PDF] academia.edu

[PDF][PDF] Safety and Immunogenicity of Different Formulations of Norovirus Vaccine Candidate in Healthy Adults: A Randomized, Controlled, Double-Blind Clinical Trial

G Leroux-Roels, JP Cramer… - The Journal of …, 2018 - academia.edu
Background. We investigated safety and immunogenicity of 1–2 doses of different bivalent
virus-like particle (VLP) norovirus vaccine candidate (NoV) formulations in healthy 18-to 64 …

Safety and Immunogenicity of Different Formulations of Norovirus Vaccine Candidate in Healthy Adults: A Randomized, Controlled, Double-Blind Clinical Trial.

G Leroux-Roels, JP Cramer… - The Journal of …, 2018 - europepmc.org
Background We investigated safety and immunogenicity of 1-2 doses of different bivalent
virus-like particle (VLP) norovirus vaccine candidate (NoV) formulations in healthy 18-to 64 …

[引用][C] Safety and Immunogenicity of Different Formulations of Norovirus Vaccine Candidate in Healthy Adults: A Randomized, Controlled, Double-Blind Clinical Trial

G Leroux-Roels, JP Cramer, PM Mendelman… - The Journal of …, 2017 - cir.nii.ac.jp
Safety and Immunogenicity of Different Formulations of Norovirus Vaccine Candidate in Healthy
Adults: A Randomized, Controlled, Double-Blind Clinical Trial | CiNii Research CiNii 国立情報学 …

Safety and immunogenicity of different formulations of norovirus vaccine candidate in healthy adults: a randomized, controlled, double-blind clinical trial

G Leroux-Roels, JP Cramer… - The journal of …, 2018 - repository.uantwerpen.be
Background. We investigated safety and immunogenicity of 1-2 doses of different bivalent
virus-like particle (VLP) norovirus vaccine candidate (NoV) formulations in healthy 18-to 64 …
[HTML] nih.gov

[HTML][HTML] Safety and Immunogenicity of Different Formulations of Norovirus Vaccine Candidate in Healthy Adults: A Randomized, Controlled, Double-Blind Clinical Trial

G Leroux-Roels, JP Cramer… - The Journal of …, 2018 - ncbi.nlm.nih.gov
Background We investigated safety and immunogenicity of 1–2 doses of different bivalent
virus-like particle (VLP) norovirus vaccine candidate (NoV) formulations in healthy 18-to 64 …

Safety and Immunogenicity of Different Formulations of Norovirus Vaccine Candidate in Healthy Adults: A Randomized, Controlled, Double-Blind Clinical Trial

G Leroux-Roels, JP Cramer… - The Journal of …, 2018 - pubmed.ncbi.nlm.nih.gov
Background We investigated safety and immunogenicity of 1-2 doses of different bivalent
virus-like particle (VLP) norovirus vaccine candidate (NoV) formulations in healthy 18-to 64 …